Answers are grounded in this paper and cite their sources.
The anabolic effects of β₂-adrenoceptor (β₂-AR) agonists on skeletal muscle have been demonstrated in various species. However, the clinical use of β₂-AR agonists for skeletal muscle wasting conditions has been limited by their undesired cardiovascular effects. Here, we describe the preclinical pharmacological profile of a novel 5-hydroxybenzothiazolone (5-HOB) derived β₂-AR agonist in comparison with formoterol as a representative β₂-AR agonist that have been well characterized. In vitro, 5-HOB has nanomolar affinity for the human β₂-AR and selectivity over the β₁-AR and β₃-AR. 5-HOB also shows potent agonistic activity at the β₂-AR in primary skeletal muscle myotubes and induces hypertrophy of skeletal muscle myotubes. Compared with formoterol, 5-HOB demonstrates comparable full-agonist activity on cAMP production in skeletal muscle cells and skeletal muscle tissue–derived membranes. In contrast, a greatly reduced intrinsic activity was determined in cardiomyocytes and cell membranes prepared from the rat heart. In addition, 5-HOB shows weak effects on chronotropy, inotropy, and vascular relaxation compared with formoterol. In vivo, 5-HOB significantly increases hind limb muscle weight in rats with attenuated effects on heart weight and ejection fraction, unlike formoterol. Furthermore, changes in cardiovascular parameters after bolus subcutaneous treatment in rats and rhesus monkeys are significantly lower with 5-HOB compared with formoterol. In conclusion, the pharmacological profile of 5-HOB indicates superior tissue selectivity compared with the conventional β₂-AR agonist formoterol in preclinical studies and supports the notion that such tissue-selective agonists should be investigated for the safe treatment of muscle-wasting conditions without cardiovascular limiting effects.
No takes yet. Share an insight, caveat, or question.
Koziczak‐Holbro et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: